Barcelona -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years dedicated to enhancing people's health and well-being and a recognized leader in plasma medicines, transfusion diagnostics and pharmaceutical specialties for hospital use, and Shanghai RAAS Blood Products Co. Ltd. (002252.SZ), a leading Chinese company in the plasma-derivatives sector, today announced the closing of their strategic alliance in China.

This transaction will increase the production, sale and development of plasma-derived products and the latest transfusion diagnostic solutions in China in adherence with international quality and safety standards.

Grifols and Shanghai RAAS will work together to ensure that all activities related to the collection of plasma and production of plasma-derived medicines comply with the strictest international quality-control mandates by virtue of the "Strategic Alliance Agreement" signed by both companies.

Through the agreement, Shanghai RAAS will also become the exclusive distributor of Grifols' plasma products and transfusion diagnostics in China.

For Grifols, the agreement offers an opportunity to bolster its international expansion and build on its long-term, sustainable growth.

With sales offices in Shanghai and Beijing, Grifols has operated in the Chinese market since the 1980s. In 2019, the company had a total of 28 registered products: five Bioscience Division products and 23 Diagnostic Division products, of which eight are NAT donor-screening solutions utilized for blood and plasma donations and 15 are blood-typing solutions. Grifols will continue its efforts to expand its portfolio of registered products in China over the coming years.

At present, China is Grifols' third-largest sales market. It represents the company's largest market for albumin and third most important market for the Diagnostic Division, with the highest sales volume of DG-Gel® cards and second-highest sales volume of Procleix® NAT Solutions in APAC.

The Chinese market holds tremendous growth potential for Grifols. Guaranteeing the safety of blood donations and transfusions is a top priority for China as part of its ongoing efforts to reform its healthcare system.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE